Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease

Liver International

Volumn 35, Issue 4, 2015, Pages 1442-1450

  Sharon, David ^a   Chen, Min ^a   Zhang, Guangzhi ^a   Girgis, Safwat ^b   Sis, Banu ^b   Graham, Don ^a   Mcdougall, Chelsea ^a   Wasilenko, Shawn T ^a   Montano Loza, Aldo ^a   Mason, Andrew L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autoimmune biliary disease; Combination antiretroviral therapy; Mouse mammary tumour virus; NOD.c3c4; Primary biliary cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GAG PROTEIN; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; LAMIVUDINE; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BILE DUCT INJURY; CHOLANGITIS; CONTROLLED STUDY; FEMALE; LIVER HISTOLOGY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PROTEIN EXPRESSION; RETROVIRUS INFECTION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; BLOOD; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LIVER CIRRHOSIS, BILIARY; MOLECULAR GENETICS; MOUSE MAMMARY TUMOR VIRUS; NONOBESE DIABETIC MOUSE; PATHOGENICITY; RETROVIRIDAE INFECTIONS; TIME; TUMOR VIRUS INFECTIONS; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTI-RETROVIRAL AGENTS; BIOMARKERS; CHOLANGITIS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; LAMIVUDINE; LIVER CIRRHOSIS, BILIARY; LOPINAVIR; MAMMARY TUMOR VIRUS, MOUSE; MICE, INBRED NOD; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS; RETROVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TIME FACTORS; TUMOR VIRUS INFECTIONS; VIRAL LOAD; ZIDOVUDINE;

EID: 84924503081     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12699     Document Type: Article

References (30)

1. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F. The genetics of complex cholestatic disorders. Gastroenterology 2013; 144: 1357-74.
2. Irie J, Wu Y, Wicker LS. et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006; 203: 1209-19.
3. Koarada S, Wu Y, Fertig N, et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 2004; 173: 2315-23.
4. Oertelt S, Lian ZX, Cheng CM, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-60.
5. Salas JT, Banales JM, Sarvide S, et al. Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008; 134: 1482-93.
6. Wakabayashi K, Lian Z-X, Moritoki Y, et al. IL-2 receptor α-/- mice and the development of primary biliary cirrhosis. Hepatology 2006; 44: 1240-9.
7. Mattner J, Savage PB, Leung P, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008; 3: 304-15.
8. Wakabayashi K, Lian ZX, Leung PS, et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 2008; 48: 531-40.
9. Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A, et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39: 151-6.
10. Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci of the U S A 2003; 100: 8454-9.
11. Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 1620-4.
12. Mason AL. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 2011; 54: 1312-4.
13. Johal H, Scott GM, Jones R, et al. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol 2009; 50: 548-54.
14. Selmi C, Ross SR, Ansari AA, et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127: 493-501.
15. Wang W, Wasilenko S, Indik S, Wong G, Mason A, et al. Isolation of the human betaretrovirus and demonstration of integration sites in patients with primary biliary cirrhosis. Can J Gastroenterol 2012; 26: 84A.
16. Zhang G, Chen M, Graham D, et al. Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. J Hepatol 2011; 55: 876-84.
17. Held W, Waanders GA, Acha-Orbea H, MacDonald HR, et al. Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med 1994; 180: 2347-51.
18. Cihlar T, Douglas JL, Gibbs CS, et al. Methods of Inhibition of MMTV-Like Viruses, U.P.a.T. Office, Editor. USA: Gilead Sciences Inc., 2005.
19. Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis. Liver Int 2009; 30: 871-7.
20. Ishak K, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
21. Mason AL, et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 2348-55.
22. Sis B, Dadras F, Khoshjou F. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant 2006; 6: 1444-50.
23. Dimai HP, Linkhart TA, Linkhart SG. Alkaline phosphatase levels and osteoprogenitor cell numbers suggest bone formation may contribute to peak bone density differences between two inbred strains of mice. Bone 1998; 22: 211-6.
24. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12(Suppl. 3): H15-23.
25. Mason AL. An autoimmune biliary disease mouse model for primary biliary cirrhosis: something for everyone. Hepatology 2006; 44: 1047-50.
26. Schembri G, Schober P. Killing two birds with one stone. The Lancet 2011; 377: 96.
27. Mason AL, Montano-Loza AJ, Saxinger L. Letter: biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis. Aliment Pharmacol Ther 2014; 39: 236-7.
28. Gallant JE, Dejesus E, Arribas JR. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
29. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28: 886-94.
30. Mason AL, Wasilenko ST. Other potential medical therapies: the use of antiviral agents to investigate and treat primary ciliary cirrhosis. Clin Liver Dis 2008; 12: 445-60; xi.